Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) Price & Performance

Amylx Pharmaceuticals IncTrade
JPMorgan Nasdaq Equity Premium Income ETFTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs JPMorgan Nasdaq Equity Premium Income ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $23.67 (market cap $2.64B), while JPMorgan Nasdaq Equity Premium Income ETF trades at $60.06. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, JPMorgan Nasdaq Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.

AMLXJEPQ
Market Cap
$2.64B
Sector
HealthIncome / Options Overlay
52-Week High
$24.19$61.46
52-Week Low
$7.82$53.77
Enterprise Value
$2.39B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.

Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.

JPMorgan Nasdaq Equity Premium Income ETF

JEPQ trades at $60.01, up 0.55% today, with a bullish technical signal from moving averages. The ETF focuses on Nasdaq-100 exposure with an options income strategy, generating monthly distributions. Recent news highlights its role in retirement income portfolios but notes tax implications for distributions. Key support sits at $59, with resistance at $60.

The outlook remains positive for income-seeking investors, supported by institutional buying and media coverage. Risks include tax treatment of distributions and market volatility affecting the underlying Nasdaq holdings. Analyst sentiment is mixed due to high RSI levels suggesting potential overbought conditions near-term.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About JPMorgan Nasdaq Equity Premium Income ETF

JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.

Read more on JEPQ